The global leader in biopharma, cell, gene, and consumer health partnerships has consolidated from four reporting segments to two
Catalent has announced changes to its operating structure and executive leadership team that went into effect July 1.
This new organisational structure includes a shift from four reporting segments to two, each representing roughly half of the total company revenue.
According to Alessandro Maselli, Catalent's President and CEO since July 1, the segment changes reflect evolving customer and industry trends and position the company to deliver its next level of growth and achievement.
This organisational restructuring has also been accompanied by a few additional leadership changes
"Our industry continues to demonstrate steady growth, and this new structure will allow us to be more agile in meeting and anticipating customer needs and expectations," said Maselli. "Among other benefits, it will create commercial synergies for our customers, as they will be better able to access the full range of Catalent services applicable to their molecules."
Aris Gennadios was named Group President of Catalent's newly formed Pharma and Consumer Health segment. The new segment consolidates the company's prior Softgel & Oral Technologies segment, which Gennadios had led since 2013, and its Oral & Specialty Delivery and Clinical Supply Services segments.
"Combining our businesses focused on the development and supply of pharmaceutical and consumer health products will provide our customers with more integrated solutions, streamlined service, and simplified delivery of the solutions they need to accelerate their path to patients and consumers," said Gennadios.
The new Pharma and Consumer Health segment will encompass the offerings of the three prior segments, including the company's market-leading softgels, Zydis fast-dissolve technologies, gummy dosage forms, clinical development and trial supply services, and global pharma manufacturing platforms. Dedicated teams will focus on Catalent’s pharmaceutical, consumer health, and clinical development and supply solutions to further drive value for customers and the opportunity for accelerated growth of these businesses.
The scope of Catalent's other reporting segment, Biologics, continues without any change.
The new Pharma and Consumer Health segment will encompass the offerings of the three prior segments, including the company's market-leading softgels, Zydis fast-dissolve technologies, gummy dosage forms, clinical development and trial supply services, and global pharma manufacturing platforms
This organisational restructuring has also been accompanied by a few additional leadership changes. Jonathan Arnold, who previously served as President, Oral & Specialty Delivery, since 2017, is Catalent's new Senior VP, Chief Commercial Officer, and Head of Transformation. He will be dedicated to ensuring a best-in-class customer experience and working closely with others on the leadership team to optimise the company's growing portfolio.
Additionally, Steven Fasman, who previously served as Senior VP and General Counsel since 2014, will be Catalent's Executive VP and Chief Administrative Officer, a newly created position. Fasman will oversee certain administrative functions of the company, including legal & compliance, information technology, engineering, procurement, governmental affairs, and various ESG-related departments.
Finally, Karen Flynn has announced her decision to retire from her role as Catalent's Senior Vice President and Chief Commercial Officer. "Karen has played a critical role on the Executive Leadership Team since joining Catalent in early 2020. I am immensely grateful for her leadership, innovative thinking, and steadfast commitment to the company," said Maselli.